August 6, 2009 Ken Stratton 774 Knoll Drive San Carlos, CA 94070 Re: Amendment to Existing Employment Agreement Dear Ken:Stemcells Inc • March 11th, 2010 • Biological products, (no disgnostic substances)
BETWEEN UNIVERSITY OF EDINBURGH (“the Licensor”) - and - STEM CELL SCIENCES LIMITED (formerly known as STEM CELL SCIENCES PTY LTD) ACN 063 293 130 (“the Licensee”) AGREEMENTUniversity of Edinburgh • March 11th, 2010 • Stemcells Inc • Biological products, (no disgnostic substances) • Victoria
Re: License Agreement, NeuroSpheres LTD, NeuroSpheres Holdings LTD, and StemCells, Inc., dated October 30, 2000 (the “Agreement”)Stemcells Inc • March 11th, 2010 • Biological products, (no disgnostic substances)
This letter (the “Letter Amendment”) will, if accepted by NeuroSpheres Ltd. and Neurospheres Holdings Ltd., constitute an amendment to the Agreement referenced above. As we have discussed, StemCells, Inc. (“StemCells”) proposes to enter a sublicense with BioWhittaker, Inc., (“BioWhittaker) under which BioWhittaker would be granted the right (retroactively, upon payment of royalties for past sales) to sell the product listed in its catalogue as CC2259 “Neural Progenitor Cells.” We ask that NeuroSpheres Ltd. and Neurospheres Holdings Ltd. agree to amend Section 3.08 of the Agreement to add the following words to the end of the first sentence: “, provided, however, that neither the entry of a sublicense between SCI and BioWhittaker, Inc. or any parent or subsidiary thereof concerning activity in the research market, nor any sales or other activity pursuant to such sublicense, shall constitute commercial sales of any licensed Product for the purposes of this Section 3.08.” That section wou
Re: License Agreement, NeuroSpheres LTD, NeuroSpheres Holdings LTD, and StemCells, Inc., dated October 30, 2000 (the “Agreement”)Stemcells Inc • March 11th, 2010 • Biological products, (no disgnostic substances)
This letter (the “Second Letter Amendment”) will, if accepted by NeuroSpheres Ltd. and Neurospheres Holdings Ltd., constitute an amendment to the Agreement referenced above. You are aware that StemCells has entered a short-term sublicence with StemCell Technologies, Inc. (STI), a Canadian corporation located in Vancouver; as we have discussed, StemCells proposes to enter a long-term sublicense with them (the “New Sublicense”. Under the New Sublicense, STI would be granted the right to make and sell certain products (at this point, we’re in discussion about the products, but they would be non-human cells and media which could include media for culturing human cells, all for the research market only) under patent rights that include patents licensed to StemCells by NeuroSpheres as well as patents of which StemCells is the owner. In order to avoid the need to enter into two separate agreements (one covering NeuroSpheres technology and the other covering StemCells’ technology), we request
Re: License Agreement, NeuroSpheres LTD, NeuroSpheres Holdings LTD, and StemCells, Inc., dated October 30, 2000 (the “Agreement”)Stemcells Inc • March 11th, 2010 • Biological products, (no disgnostic substances)
This letter (the “Third Letter Amendment”) will, if accepted by NeuroSpheres Ltd. and Neurospheres Holdings Ltd., constitute an amendment to the Agreement referenced above.
